US OptionsDetailed Quotes

IMMP241220C2500

Watchlist
  • 0.05
  • 0.000.00%
15min DelayClose Nov 29 13:00 ET
0.00High0.00Low

Immutep Stock Discussion

Sign in to post a comment
    我要向钱看
    我要向钱看
    Nov 21 20:43
    LOOKING REAL GOOD...
    Immutep Limited Passes All AGM Resolutions
    Immutep Ltd (AU:IMM) has released an update.
    Immutep Limited announced that all resolutions proposed at their 2024 Annual General Meeting were successfully passed, showcasing strong shareholder support. The company, a leader in LAG-3 immunotherapy for cancer and autoimmune diseases, continues to focus on advancing its innovative treatment options. This positive outcome is likely to strengthen investor confidence and potentially i...
    我要向钱看
    我要向钱看
    Nov 21 19:59
    UPDATES
    $Immutep (IMMP.US)$ Immutep (ASX:IMM) will focus on developing its cancer treatment lead candidate eftilagmod alpha in fiscal 2025, Chair Russel Howard said at the annual general meeting, according to a Friday filing with the Australian bourse.
    The lead candidate will be evaluated in the phase 3 TACTI-004 trial to investigate its use in patients with first-line non-small cell lung cancer. The trial is set to start later in the year or early next year, the filing said.
    The biotechnology f...
    我要向钱看
    我要向钱看
    Nov 18 00:30
    ON THE WATCH LIST
    $Immutep (IMMP.US)$
    Add AU:IMM to your watchlist
    Immutep Ltd has witnessed a notable increase in its voting power, with Regal Funds Management Pty Limited and its associates now holding 11.79% of the company’s shares, up from 10.59%. This shift, involving various financial entities like UBS and Merrill Lynch, highlights a growing interest in Immutep’s market potential. Investors keen on stock dynamics should keep an eye on these developments for future implications.
    我要向钱看
    我要向钱看
    Nov 15 06:53
    UPDATES
    $Immutep (IMMP.US)$ Baird analyst Joel Beatty maintains $Immutep (IMMP.US)$ with a buy rating, and adjusts the target price from $6 to $7.
    我要向钱看
    我要向钱看
    Nov 14 07:36
    UPDATES
    $Immutep (IMMP.US)$ 
    Immutep (IMMP) announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in combination with radiotherapy plus KEYTRUDA for patients with soft tissue sarcoma, STS, at the Connective Tissue Oncology Society, CTOS, 2024 Annual Meeting. Based on preliminary analysis among 21 patients available for primary endpoint assessment, the triple combination therapy demonstrates significant efficacy in the neoadjuvant se...
    我要向钱看
    我要向钱看
    Nov 14 07:19
    UPDATES
    $Immutep (IMMP.US)$ Immutep Announces Data From Phase II Trial In Soft Tissue Sarcoma Presented At CTOS 2024 Annual Meeting; Efti In Combination With Pembrolizumab And Radiotherapy Demonstrates Significant Efficacy In The Neoadjuvant Setting In Patients With Soft Tissue Sarcoma
    我要向钱看
    我要向钱看
    Nov 14 00:00
    UPDATES
    $Immutep (IMMP.US)$ Biotechnology company Immutep (ASX:IMM) obtained positive survival data from the Insight-003 first phase trial, evaluating eftilagimod alpha in combination with Keytruda and chemotherapy for the first-line treatment of metastatic non-squamous non-small cell lung cancer, according to a Thursday filing with the Australian bourse.
    The study results, with a minimum follow-up of 22 months, showed a median overall survival of 32.9 months, a median progression-free survival o...
    我要向钱看
    我要向钱看
    Nov 13 17:08
    UPDATES
    $Immutep (IMMP.US)$ Immutep Ltd (AU:IMM) has released an update.
    Immutep Ltd has unveiled promising Phase II trial results for its novel combination therapy involving eftilagimod alpha, pembrolizumab, and radiotherapy in treating soft tissue sarcoma. The trial demonstrated a significant increase in tumor hyalinization, suggesting improved outcomes and survival rates for patients. With over 71% of participants showing a pathologic response, the therapy showcases potential in addressing thi...
    Trytosaveabit
    Trytosaveabit
    Oct 28 07:12
    Watching
    $Immutep (IMMP.US)$ Immutep To Present New Phase IIb Data In PD-L1 Negative Head And Neck Cancer At ESMO Immuno-Oncology 2024
    Benzinga· just
    Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it will present new data from Cohort B of the TACTI-003 Phase IIb trial in first line recurrent/metastatic head and neck squamous cell carcinoma patient...
    我要向钱看
    我要向钱看
    Oct 22 02:39
    LATEST REPORT
    $Immutep (IMMP.US)$ Immutep (ASX:IMM) has released its annual report, detailing significant progress over the past year with its lead immunotherapy candidate eftilagimod alpha (efti). This drug is designed to activate the body’s immune system to better recognise and attack cancer cells. It targets LAG-3, a protein that plays a key role in regulating immune responses. Specifically, efti stimulates antigen-presenting cells (APCs), which are essential for initiating the body’s immune d...

No comment yet